$23.12
1.81% day before yesterday
NYSE, Dec 24, 11:00 pm CET
ISIN
US03969F1093
Symbol
RCUS

Arcus Biosciences Stock price

$23.12
-0.06 0.26% 1M
+14.37 164.23% 6M
+8.23 55.27% YTD
+7.21 45.32% 1Y
+2.71 13.28% 3Y
-7.46 24.40% 5Y
+6.12 36.00% 10Y
+6.12 36.00% 20Y
NYSE, Closing price Wed, Dec 24 2025
+0.41 1.81%

Key metrics

Basic
Market capitalization
$2.9b
Enterprise Value
$2.1b
Net debt
positive
Cash
$831.0m
Shares outstanding
107.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
11.9 | 11.4
EV/Sales
8.9 | 8.5
EV/FCF
negative
P/B
6.6
Financial Health
Equity Ratio
42.2%
Return on Equity
-58.4%
ROCE
-50.7%
ROIC
-767.6%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$240.0m | $251.4m
EBITDA
$-365.0m | $-370.5m
EBIT
$-375.0m | $-404.6m
Net Income
$-341.0m | $-382.0m
Free Cash Flow
$-464.0m
Growth (TTM | estimate)
Revenue
-8.8% | -2.6%
EBITDA
-26.7% | -23.5%
EBIT
-25.8% | -30.5%
Net Income
-26.3% | -35.0%
Free Cash Flow
-174.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-152.1% | -147.4%
EBIT
-156.3%
Net
-142.1% | -152.0%
Free Cash Flow
-193.3%
More
EPS
$-3.2
FCF per Share
$-4.3
Short interest
9.0%
Employees
627
Rev per Employee
$410.0k
Show more

Is Arcus Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Arcus Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Arcus Biosciences forecast:

15x Buy
83%
3x Hold
17%

Analyst Opinions

18 Analysts have issued a Arcus Biosciences forecast:

Buy
83%
Hold
17%

Financial data from Arcus Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
240 240
9% 9%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 112 112
7% 7%
47%
- Research and Development Expense 503 503
14% 14%
210%
-365 -365
27% 27%
-152%
- Depreciation and Amortization 10 10
0% 0%
4%
EBIT (Operating Income) EBIT -375 -375
26% 26%
-156%
Net Profit -341 -341
26% 26%
-142%

In millions USD.

Don't miss a Thing! We will send you all news about Arcus Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcus Biosciences Stock News

Neutral
Business Wire
7 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Fr...
Positive
Seeking Alpha
9 days ago
RCUS is now resetting its strategy after its Phase 3 STAR-221 was discontinued. This removes domvanalimab for upper-GI cancers as a key catalyst. Instead, they'll focus now on Casdatifan (AB521), which is a wholly owned oral HIF-2α inhibitor. In my view, this makes Casdatifan the core bull thesis, especially with the Phase 3 PEAK-1 results going forward.
Neutral
Investors Business Daily
14 days ago
Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.
More Arcus Biosciences News

Company Profile

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Head office United States
CEO Terry Rosen
Employees 627
Founded 2015
Website arcusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today